Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
How Diddy made himself the 'victim' in apology video where he does not mention ex
Sean 'Diddy' Combs made himself sound like a victim in the Instagram apology video he posted in the2024-05-22Government increases support for Ukraine, extends NZDF deployment
Photo: RNZ / Samuel Rillstone2024-05-22Elly De La Cruz homers again as the Reds pound the White Sox 11
CHICAGO (AP) — Elly De La Cruz hit a three-run drive for his fourth homer in his last four games, he2024-05-22- NEW YORK (AP) — A baseball agent at Bad Bunny’s Rimas Sports firm has lost his certification with th2024-05-22
Company wins court ruling to continue development of Michigan factory serving EV industry
GREEN TOWNSHIP, Mich. (AP) — A judge has ordered a Michigan community to stop blocking efforts to br2024-05-22Trump assails Jewish voters who back Biden: 'Should have their head examined'
ATLANTA (AP) — Donald Trump on Wednesday lashed out at Jewish voters who back President Joe Biden an2024-05-22
atest comment